The objective of this study was to establish whether genetic polymorphisms that could be related to angiotensin-converting enzyme (ACE) levels are associated with hypertension. A total of 10 haplotype-tagging single-nucleotide polymorphisms in ACE, the ACE I/D polymorphism, and 2 polymorphisms in the ABO (rs495828 and rs8176746) were investigated for association with hypertension in 269 hypertensive patients and 254 healthy controls. All analyses were adjusted for age and body mass index, and corrected for multiple testing. Only one polymorphism of the ABO gene (rs495828) presented nominal pointwise Po0.05 values (odds ratio¼0.33, 95% CI 0.19-0.58, P¼6Â10 À5 ) and achieved Po3.8Â10 À3 , the nominal P-value considered significant after Bonferroni correction. Analysis of the genotype frequencies showed that the model that correctly explained the observed association was the recessive model (odds ratio¼0.03, 95% CI 0.01-0.15, P¼1Â10 À6 ). These results indicate that genetic variants that could be related to ACE activity are good predictors of hypertension, and identify ABO as a good candidate gene for genetic studies of hypertension risk. Further studies are required to confirm this association.
INTRODUCTION
Hypertension has been considered a complex and polygenic trait. The risk of hypertension is known to be partially inherited, but although a high heritability has been described for blood pressure and hypertensive traits, no clearly reproducible genetic variants have been found for hypertension.
A large number of candidate genes have been tested for association with blood pressure and hypertensive traits without convincing results. 1 Candidate genes have been selected from physiologically related systems implicated in blood pressure regulation, especially the renin-angiotensin system. 2 The renin-angiotensin system is known to influence all aspects of blood pressure control, including blood vessel contraction, sodium balance and cell development in the heart. 3 One of the most studied genes is that of the angiotensinconverting enzyme (ACE). Elevated ACE levels have been reported in patients with heart failure, 4 and animal studies have demonstrated that the ACE gene is associated with blood pressure. 5 Conflicting results have been published regarding the association of ACE variants with hypertension, although two meta-analyses were unable to detect an independent association of the ACE I(insertion)/D(deletion) polymorphism with hypertension. 6, 7 This polymorphism, corresponding to a 287-base-pair insert in intron 16 of the gene, is associated with the ACE concentration in blood and tissues, subjects with one or two D alleles having B30 and 60% higher ACE levels, respectively, than subjects with the II genotype. 8 The ACE I/D polymorphism was originally proposed to account for 47% of the total phenotypic variance of circulating ACE. More recent investigations suggest that this percentage is much lower, possibly even close to 10%. 9 Thus, it is now estimated that the I/D polymorphism accounts for o20% of ACE variability. 10 The role of other genetic variants in the ACE gene that may modulate ACE levels and activity cannot be excluded. Furthermore, recent genome-wide association studies (GWAS) for ACE enzyme activity found a strong association between one polymorphism in the ACE gene (rs4343) (P¼8.6Â10 À21 ) and two polymorphisms in the ABO gene (rs495828 and rs8176746) (P¼2.5Â10 À8 and P¼2.5Â10 À6 ) with increased activity in 400 Han Chinese; these associations were replicated in two independent cohorts. 11 The rs4343 polymorphism is in high-moderate linkage disequilibrium (LD) with rs4305, a polymorphism of the ACE gene that has been related to the risk of hypertension (P¼3.0Â10 À5 ) in a study compromising 23 cohorts of three independent studies (Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Global BPgen Consortium; and Women's Genome Health Study) and a total of 86 588 individuals. 12 In a previous study, we associated the minor allele of the rs495828 polymorphism of the ABO gene with the incidence of cough induced by treatment with ACE inhibitors in females (P¼6.0Â10 À4 ). 13 According to the hypothesis that ACE activity could be an important marker of hypertension risk, our objective is the identification of genetic polymorphisms associated with hypertension risk that are related to this quantitative trait. As several polymorphisms in the ACE gene have been related to the level of ACE activity in different populations, we included a complete analysis of genetic variability of the ACE gene, using an extensive LD mapping approach with haplotype-tagging single-nucleotide polymorphisms (SNPs) selected from HapMap data for this gene. 14 In addition, three polymorphisms that have been related to ACE levels were added to this selection: the ACE I/D polymorphism (rs4340), 8 and two polymorphisms in the ABO gene (rs495828 and rs8176746). 11 
METHODS Subjects
A cohort of 281 patients who had been treated with ACEi was retrospectively recruited at the Les Corts primary care center (Barcelona, Spain) and the Hospital Clínic (Barcelona, Spain). Of these, 12 cases were excluded as they presented concomitant diseases (coronary artery disease, heart failure, diabetes or chronic renal failure). A total of 269 patients with a diagnosis of hypertension participated in the present study. Hypertension was defined as a systolic blood pressure X140 mm Hg and/or a diastolic blood pressure X90 mm Hg. The control group consisted of 373 subjects who were consecutively recruited at the Trauma Service of the Hospital Clínic and who had previously participated in genetic studies. 15, 16 Most of the controls were admitted for hip or knee joint replacement, pelvic fracture or injury to the upper or lower ribs. Of these, 254 individuals without a clinical history of hypertension, diabetes, cardiovascular or renal disease participated in the present study. A questionnaire was administered to each patient in an interview, which elicited demographic information, data on occupation and smoking habits, and personal medical history. The clinical information obtained was checked by examining clinical records.
All study participants were Caucasians who lived in Catalonia. Catalonia is a region in northeast Spain with 7 210 508 inhabitants, 96.2% of whom are Caucasian (http://www.idescat.cat/cat/idescat/publicacions/anuari/). Ethnicity was determined by self-reported ancestries: the cases and controls reported the ethnicity of each grandparent. We excluded subjects who mentioned nonEuropean grandparents. Written informed consent was obtained from each subject. The study was approved by the hospital's ethics committee.
Sample preparation
Blood samples were collected from the participating individuals in EDTA (K2EDTA BD Vacutainer EDTA tubes; Becton Dickinson, Franklin Lakes, NJ, USA) and genomic DNA was isolated using a DNA purification kit (Puregene; Gentra Systems, Indianapolis, IN, USA). The DNA concentration was determined by absorbance (ND1000, NanoDrop, Willmington, DE, USA).
SNP selection, genotyping and quality control
A total of 13 SNPs were selected from the ACE gene region (covering target loci and regions 10-Kb upstream and 10-Kb downstream) by tagging analysis (as implemented in Haploview 4.1 (http://broad.mit.edu/mpg/haploview)) at an r 2 threshold of 0.8. The aim was to capture 98% of the most common HapMap phase II variants, based on the CEU panel (minor allele frequency 40.1; Hardy-Weinberg equilibrium Po0.05; minimum genotyping rate 485%). One SNP was rejected before genotyping owing to the assay rules. The remaining 12 tag SNPs were genotyped using the MassARRAY genotyping system (Sequenom Inc., San Diego, CA, USA) at the Santiago de Compostela Node of the Spanish National Genotyping Center (CeGen). We excluded two SNPs whose genotypes were called in o90% of samples or that had inconsistent clustering on inspection. The 10 validated SNPs tagged 90% of the most common HapMap II variants (minor allele frequency 40.05).
For quality control, eight samples were genotyped in duplicate for all the SNPs analyzed, with a concordance rate of 100%.
Three SNPs were added to this selection: the ACE I/D polymorphism, which is the most common polymorphism in the ACE gene (rs4340), and two polymorphisms in the ABO gene that have been related to ACE levels (rs495828 and rs8176746). The ACE I/D polymorphism was genotyped by conventional PCR, as described previously. 17 The genotyping of rs495828 and rs8176746 was assessed using TaqMan s genotyping assays (Applied Biosystems, Foster City, CA, USA).
Statistics
Sample size and statistical power were calculated using Quanto1.2. software (http://hydra.usc.edu/gxe). Given the recruited sample size, and assuming a 5% level of significance, we were able to detect odds ratio values of 41.85 with 483% statistical power when polymorphisms with allele frequencies of 40.1 were analyzed. Data were analyzed using SPSS14.05 (statistical analysis software, SPSS Inc., Chicago, IL, USA). Means and s.d.'s were computed for continuous variables. Univariate analysis (the w 2 test for categorical variables and the Student t-test for continuous variables) was used to identify variables associated with elevated risk of hypertension. Three variables were considered: age, sex and body mass index (BMI). The analysis was adjusted for the variables that were significantly associated with increased risk of hypertension (age and BMI). These variables were included in the logistic regression models used for the analysis. The best model was selected using the Akaike information criteria, using the SNPassoc R package. 18 Hardy-Weinberg equilibrium and LD relationships between polymorphisms and haplotype block structures were evaluated using Haploview software v.3.2 (http://broad.mit.edu/mpg/haploview). For the haplotype estimations, we used a sliding windows approach in the haplo.stats R package. To avoid false-positive results caused by multiple testing, the Bonferroni correction was applied; given that 13 polymorphisms were analyzed, significant results were considered when Po3.8Â10 À3 . Table 1 summarizes the characteristics of the study population. The case group was older (P¼1Â10 À6 ) and had a higher BMI (P¼2Â10 À7 ) than the control group. The statistical analysis was adjusted to account for these factors. To avoid the possible confounding effect of these variables, we tested the possible associations of the genotypes included in the study with the clinical variables recorded. None of the polymorphisms tested showed significant associations with any of the variables considered.
RESULTS
The results of the allelic association analysis for single SNPs are shown in Table 2 . All polymorphisms analyzed were in HardyWeinberg equilibrium. Only one polymorphism of the ABO gene (rs495828) presented nominal pointwise Po0.05 values (odds ratio¼0.33, 95% CI 0.19-0.58, P¼6Â10 À5 ) and achieved Po3.8Â10 À3 , the nominal P-value considered significant after Bonferroni correction. Analysis of the genotype frequencies under codominant, dominant, overdominant, recessive and additive models revealed that the model that correctly explained the observed association of rs495828 was the recessive model (P¼1Â10 À6 ) ( Table 3) .
None of the haplotypes constructed in the ACE gene were significantly associated with hypertension, not even the haplotype blocks that included SNPs that were significantly associated with this disease in the literature (ACE I/D, rs4305, rs4343).
DISCUSSION
The aim of the present study was to evaluate the possible association between genetic variability and candidate polymorphisms in genes related to ACE levels (ACE and ABO), and the risk of hypertension. This is the first time that the ABO gene has been linked with hypertension. This genetic study revealed an association between hypertension and a genetic polymorphism in the ABO gene. These results are consistent with the proposed role of this gene in ACE activity. 11 ACE activity represents an upstream and internal facet of hypertension, and has reasonably high heritability 19 and low intra-individual variation. 20 It could be considered a 'good intermediate phenotype' or endophenotype for predicting risk of hypertension. 11, 21 Recently, a genome-wide analysis of the quantitative trait of ACE identified three polymorphisms as good predictors of ACE activity: rs4343 (ACE), rs495828 and rs8176746 (ABO). 11 We included these three polymorphisms in our study and found a strong association between rs495828 and hypertension. In our population, carriers of the T allele, who have lower ACE levels according to Chung et al., 11 had a lower risk of developing hypertension.
ABO encodes glycosyltransferases, which transfer monosaccharides to the cell-surface H antigens. As ACE molecules are carriers of ABO antigens, oligosaccharide moieties on ABO antigens that are bound covalently to the ACE molecules may affect the aqueous solubility of ACE and its susceptibility to proteases, resulting in the release of varying amounts of active enzyme. The association of the ABO blood group system with hypertension is not a new idea. Cidl et al. 22 found an independent effect of the ABO blood group on ACE serum activity. The different glycosylation of the ACE molecule in different ABO blood groups seems to modulate the regulation of blood pressure in a given subject depending on the genetic variants of glycosylated genes. Moreover, Vasku et al. 23 identified an association of blood pressure with ACE I/D polymorphism and ABO blood group. The differences in the distribution of these ABO groups among ethnicities could explain the ethnic differences observed in the incidence of hypertension.
We found no significant associations with rs4343, the ACE polymorphism proposed to explain the highest percentage of ACE activity in a Han Chinese population. 11 It does not introduce any change into the amino-acid sequence of the ACE protein. Given that this is a synonymous SNP, and the existing differences in LD relationships among SNPs across different populations, we cannot rule out the possibility that rs4343 could be a marker polymorphism rather than a causal variant. rs4305 (Hapmap Caucasian population D¢¼0.86) may mark the same functional variant.
In our study, no association with hypertension was observed for the ACE I/D polymorphism although it has been linked with hypertension [24] [25] [26] [27] [28] and ACE levels. 8, 20, 29 However, after being a focus of research Abbreviations: AIC, Akaike information criterion; BMI, body mass index; OR, odds ratio; 95% CI, 95% confidence interval. In bold the best model according to the Akaike information criteria (AIC).
for more than two decades, the clinical significance of the ACE I/D has yet to be established. 30 Our results highlight the importance of genetic determinants of ACE levels as good predictors of hypertension, and identify ABO as a good candidate gene for genetic studies of hypertension risk. This gene has not been linked with hypertension previously, either in the candidate gene approach or in GWAS. To date, 13 GWAS on blood pressure and hypertension have been published, including studies whose main objective was not blood pressure genetics. 31 Only 1 SNP reached genome-wide significance for hypertension in a primary GWAS meta-analysis, whereas in the same study 10 SNPs reached this threshold for systolic or diastolic blood pressure. 32 It is possible that the differences in the number of significant findings are due to differences in power; continuous traits have greater power than discrete traits, and therefore the chances of obtaining a significant result are higher with continuous traits. Indeed, many factors contribute to the inter-and intra-individual variability in blood pressure. Some have correctly argued that blood pressure in genomic studies is suboptimal because it is generally limited to a few measurements at a given point in time. 33 In total, 14 independent loci have been identified for blood pressure traits that reached genome-wide significance, including replication in independent cohorts. 32, 34, 35 These 14 loci are in or near genes encoding six enzymes (including three kinases and one cytochrome), two solute channels, two transcription factors, one growth factor, one cell signaling protein, one structural protein and one hypothetical gene. Of these genes, only 2 out of 14 (CYP17A1 and MTHFR) would have been identified as a blood pressure candidate gene before these studies. All of the other genes closest to the variants identified were previously largely unsuspected for involvement in blood pressure regulation.
Our study is not free of shortcomings. First, the sample size used in the present study is much smaller than those presented in the largest cohorts for the study of hypertension; however, we had enough statistical power to detect the significant associations described here. Given our sample size, polymorphisms were selected with allelic frequencies 410% to achieve the desired statistical power. Second, cases were recruited to participate in a pharmacogenetic study of ACE inhibitors. 13 For this reason, all cases were being treated with this antihypertensive drug. Thus, our group of cases could represent a clinical subgroup of the disease. Although this provided us with a more homogenous sample, our significant associations may not be predictive in the overall group of hypertension patients. Moreover, taking into account the BMI value in our group of cases, it may be that our cohort represents overweight hypertensive patients who may not be representative of overall hypertensive patients. Third, our groups of cases and controls differed in terms of age and BMI, two risk factors for hypertension. However, to avoid any confounding effect of these variables, both age and BMI were included as covariables in the statistical analysis. We are aware that other risk factors exist for hypertension, including diabetes, sex, dyslipidemia, smoking and alcohol intake. 35, 36 In our study, the cases and controls had a similar sex distribution, and none of the participant had a diagnosis of diabetes, as it was an exclusion criteria in both. For these reasons no adjustment is needed for these variables. However, we have no data for other risk factors such as dyslipidemia, smoking or alcohol intake. Our results could be biased owing to these risk factors, and we cannot rule out the possibility that our significant results are associated with these variables rather than the genetic risk of hypertension. Finally, although we assume that most of the patients participating in this study presented essential hypertension, we cannot role out the possible existence of secondary hypertension in some cases. For this reason, our cohort may contain a mixed phenotype of essential and secondary hypertension.
In conclusion, our study showed the influence of the ABO gene on hypertension. These results indicate that genetic variants that could be related to ACE activity are good predictors of hypertension. Further studies are required to confirm this association. If confirmed, it should be included in clinical practice as a possible risk factor for hypertension.
